Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB122 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BIIB122 225 mg | EXPERIMENTAL | Oral 225 mg dose, once daily (QD) |
| BIIB122 Matching Placebo | PLACEBO_COMPARATOR | Oral BIIB122 matching placebo, once daily (QD) |
| Name | Type | Description |
|---|---|---|
| BIIB122 225 mg | DRUG | Administered as specified in the treatment arm |
| BIIB122-Matching Placebo | OTHER | Administered as specified in the treatment arm |
Inclusion Criteria: * For heterozygous pathogenic LRRK2 mutation carriers: ≥ 30 to ≤ 80 years * For homozygous pathogenic LRRK2 mutation carriers: ≥ 30 years * Have screening genetic test results verifying the presence of a pathogenic LRRK2 variant. * Have a clinical diagnosis of PD meeting the Mov...
Top 20 of 22 competitors
BIIB122 is an investigational small molecule being studied for the treatment of Parkinson Disease, specifically in participants with LRRK2-associated Parkinson's disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
BIIB122 targets LRRK2, a protein kinase implicated in the pathogenesis of Parkinson's disease. By inhibiting LRRK2, the drug aims to modulate a key genetic and molecular pathway involved in the disease process.
BIIB122 is being developed by Denali Therapeutics Inc., a biopharmaceutical company focused on neurodegenerative diseases. The company's stock is traded under the ticker symbol DNLI.
BIIB122 is currently in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 2 trial is evaluating its safety and pharmacodynamic effects in participants with LRRK2-associated Parkinson's disease.
BIIB122 is being studied in a Phase 2 clinical trial with the identifier NCT06602193. This randomized, double-blind, placebo-controlled trial is assessing the safety and pharmacodynamic effects of BIIB122 in participants with LRRK2-associated Parkinson's disease, with an enrollment of 50 participants across the United States, Germany, Israel, and Spain.
Yes, BIIB122 is also known as BIIB122 225 mg, which refers to the 225 mg dose strength of the drug being evaluated in clinical trials. Both names refer to the same investigational small molecule developed by Denali Therapeutics.